JAK Inhibitor Crystal Forms for Selective JAK1/TYK2 Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing JAK inhibitors lack specificity and can affect various cell types, leading to safety concerns and reduced efficacy due to their broad action on cytokines, while selective JAK1 or TYK2 inhibitors are needed for targeted disease treatment.
Innovation Solution
Development of crystalline forms of a JAK inhibitor with specific diffraction peaks and thermal stability, enhancing solubility and stability, allowing for targeted treatment of JAK1 and/or TYK2-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If broad-spectrum JAK inhibitors are used, then they can inhibit multiple cytokines and show broad therapeutic effects, but they affect various cell types leading to safety concerns and reduced efficacy
Solution Approach 1:
The patent segments the JAK inhibitor activity into selective targets (JAK1 and/or TYK2) rather than broad-spectrum inhibition. The compound is designed to specifically inhibit certain JAK family members while sparing others, thereby maintaining therapeutic efficacy for specific diseases while reducing off-target effects on unrelated cell types and cytokines.
Solution Approach 2:
The patent applies local quality by creating a JAK inhibitor with non-uniform selectivity across the JAK family. The compound exhibits differential inhibition patterns (e.g., selective JAK1/ TYK2 inhibition with sparing of JAK2/JAK3), allowing targeted therapeutic action on specific pathological pathways while preserving normal physiological functions mediated by other JAK members.
2Reliability
If selective JAK1 or TYK2 inhibitors are developed, then targeted disease treatment is achieved, but the compound requires enhanced stability and solubility for effective drug delivery
Solution Approach 1:
The patent employs parameter changes by optimizing the crystalline form of the JAK inhibitor compound. Different crystal polymorphs (Forms A, B, C, D) are identified with distinct properties including solubility, stability, and bioavailability. This allows selection of the optimal crystalline form that balances selective inhibition capability with adequate pharmaceutical properties for effective drug delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms of the JAK inhibitor demonstrate improved stability, solubility, and selective inhibition of JAK1 and TYK2, providing a broader therapeutic window and enhanced safety for treating diseases like rheumatoid arthritis.
Implementation Method 1
characteristic diffraction peaks shown in a X-ray powder diffraction (XRPD) spectrum at the following 2θ angle: 6.91±0.20°, 12.21±0.20° and 19.06±0.20°
Implementation Method 2
an endothermic peak value respectively at 152.19±3° C. and 216.79±3° C. on a differential scanning calorimetry curve, and an exothermic peak value at 161.50±3° C.
Data Source
AI summary
The present invention discloses the crystal forms as a JAK inhibitor and their application in the preparation of drugs for the treatment of JAK1 or/and TYK2 related diseases.